The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

Frontiers in Oncology

Oncology

Luyao Wang¹  Ziyi Li¹  Xiangpeng Dai¹  Yurong Chen¹  Xinrui Liu² 

[1] Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China;National-Local Joint Engineering Laboratory of Animal Models for Human Disease, First Hospital, Jilin University, Changchun, China;Neurosurgery Department, First Hospital, Jilin University, Changchun, China;

关键词: cancer;    CRISPR/Cas9;    immunotherapy;    oncolytic viruses;    immune checkpoints inhibition;    CAR-T therapy;   

DOI  :  10.3389/fonc.2021.704999

 received in 2021-05-04, accepted in 2021-12-27,  发布年份 2022

来源: Frontiers

【 摘 要 】

Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9), as a versatile genome engineering tool, has become popular in the biology research field and it was also applied to optimize tumor immunotherapy. Moreover, CRISPR-based high-throughput screening can be used in the study of immunomodulatory drug resistance mechanism. In this review, we summarized the development as well as the application of CRISPR/Cas9 technology in the cancer immunotherapy and discussed the potential problems that may be caused by this combination.

【 授权许可】

Unknown   
Copyright © 2022 Wang, Chen, Liu, Li and Dai